Johnson & Johnson Acquires Shockwave Medical

The acquisition, valuing Shockwave at $335 per share, is set to enhance J&J's cardiovascular treatment portfolio.

Johnson & Johnson (J&J) announces the acquisition of Shockwave Medical for approximately $13.1 billion, aiming to bolster its cardiovascular treatment offerings.
The deal, expected to close by mid-2024, values Shockwave at $335 per share, a 4.7% premium over its closing price the day before the announcement.
Shockwave Medical specializes in intravascular lithotripsy technology, which uses sound waves to break up calcification in heart vessels, addressing coronary and peripheral artery diseases.
The acquisition is part of J&J's strategic focus on expanding its medical technology portfolio, following previous purchases such as Abiomed and Laminar for cardiovascular interventions.
Financial analysts view this acquisition as a significant move for J&J, potentially diluting its shares by about 10 cents in 2024 and 17 cents in 2025, but offering a new cardiology platform and technology.